JPH0892124A - Anti-retrovirus agent - Google Patents
Anti-retrovirus agentInfo
- Publication number
- JPH0892124A JPH0892124A JP6222801A JP22280194A JPH0892124A JP H0892124 A JPH0892124 A JP H0892124A JP 6222801 A JP6222801 A JP 6222801A JP 22280194 A JP22280194 A JP 22280194A JP H0892124 A JPH0892124 A JP H0892124A
- Authority
- JP
- Japan
- Prior art keywords
- duramycin
- hiv
- lanthiopeptin
- active ingredient
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、環状ペプチド化合物を
有効成分として含有する抗レトロウイルス剤に関するも
のであり、特にヒト免疫不全ウイルスによる感染症の治
療又は予防に使用することができる。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an antiretroviral agent containing a cyclic peptide compound as an active ingredient and can be used particularly for treating or preventing infectious diseases caused by human immunodeficiency virus.
【０００２】[0002]
【従来の技術】従来、ランチオペプチン（Lanthiopepti
n ）は、免疫増強作用・抗ヘルペス作用を有することが
知られているが、その他の作用−特に免疫不全症を引き
起こすヒト免疫不全症ウイルス（以下『ＨＩＶ』と略
記）に対する効果に関しては全く知られていなかった。
また、ランチオペプチン（Lanthiopeptin ）と類似構造
を有するデュラマイシン（Duramycin ）についても、同
様の効果に関しては全く知られていなかった。2. Description of the Related Art Conventionally, Lanthiopepti (Lanthiopepti)
n) is known to have immunopotentiating and anti-herpes actions, but is completely unknown regarding other actions-in particular, the effect on human immunodeficiency virus (hereinafter abbreviated as "HIV") that causes immunodeficiency. It wasn't done.
In addition, duramycin, which has a structure similar to that of lanthiopeptin, was not known at all for the same effect.
【０００３】他方、後天性免疫不全症候群（以下『ＡＩ
ＤＳ』と略記）の患者は全世界的に増加傾向にある。特
に東南アジアを中心とするアジア地域においてはＡＩＤ
Ｓの原因であるヒト免疫不全ウイルスの感染爆発の状態
にあり、今後ＡＩＤＳ患者はこれらの地域を中心に急増
すると考えられている。On the other hand, acquired immunodeficiency syndrome (hereinafter referred to as "AI
The number of patients with "DS" (abbreviated as ") is increasing worldwide. Especially in Asia, especially in Southeast Asia, AID
The human immunodeficiency virus, which is the cause of S, is in a state of infection and explosion, and it is considered that AIDS patients will increase rapidly mainly in these regions in the future.
【０００４】現在、抗ＨＩＶ効果を有するＡＩＤＳ治療
薬又は予防薬としては、核酸系化合物のアジドチミジン
（以下、『ＡＺＴ』と略記）、2',3'-ジデオキシシチジ
ン（以下、『ＤＤＣ』と略記）及び2',3'-ジデオキシイ
ノシン（以下、『ＤＤＩ』と略記）の３種類がＡＩＤＳ
治療薬として認可を受けており、これらの核酸系薬物は
ＨＩＶのライフサイクルにおける逆転写過程に作用する
ことにより抗ＨＩＶ活性を発揮するものと考えられてい
るが、薬剤耐性株の出現による抗ＨＩＶ活性の減少ある
いは消失、強度の副作用等により長期連続投与が不可能
といった問題があった。従って、抗ＨＩＶ活性に優れ、
かつ、低毒性の抗ＨＩＶ剤あるいは抗ＨＩＶ剤となりう
るリード化合物を探索・提供することは、ＡＩＤＳ治療
又は予防をより効果的なものとするために緊急かつ、重
要な課題となっている。Currently, AIDS therapeutic or prophylactic agents having anti-HIV effects include nucleic acid compounds azidothymidine (hereinafter abbreviated as "AZT"), 2 ', 3'-dideoxycytidine (hereinafter abbreviated as "DDC"). ) And 2 ', 3'-dideoxyinosine (hereinafter abbreviated as "DDI") are AIDS.
It has been approved as a therapeutic drug, and these nucleic acid drugs are considered to exert anti-HIV activity by acting on the reverse transcription process in the life cycle of HIV. There has been a problem that long-term continuous administration is impossible due to a decrease or disappearance of activity, a strong side effect and the like. Therefore, it has excellent anti-HIV activity,
In addition, it is an urgent and important task to search for and provide a low toxicity anti-HIV agent or a lead compound that can be an anti-HIV agent in order to make AIDS treatment or prevention more effective.
【０００５】[0005]
【発明が解決しようとする課題】そこで本発明者等は、
上記の欠点を解決すべく鋭意検討を重ねた結果、ある種
のポリペプチド化合物が抗ＨＩＶ効果を有することを見
い出し、本発明に到達した。従って、本発明の目的は、
新規な抗ＨＩＶ治療薬又は予防薬を提供することにあ
る。Therefore, the present inventors
As a result of intensive studies to solve the above-mentioned drawbacks, the inventors have found that a certain type of polypeptide compound has an anti-HIV effect, and arrived at the present invention. Therefore, the object of the present invention is to
It is intended to provide a novel anti-HIV therapeutic drug or preventive drug.
【０００６】[0006]
【課題を解決するための手段】本発明の上記の目的は、
ランチオペプチン（Lanthiopeptin ）又はデュラマイシ
ン（Duramycin ）を有効成分とする抗レトロウイルス剤
により達成された。The above objects of the present invention are as follows.
This was achieved by an antiretroviral agent containing Lanthiopeptin or Duramycin as an active ingredient.
【０００７】以下、本発明の抗レトロウイルス剤につい
て説明する。The antiretroviral agent of the present invention will be described below.
【０００８】本発明におけるランチオペプチン（Lanthi
opeptin ）は、T.Miyaki等の方法（The Journal of Ant
ibiotics：Vol.XLII,No.6, P837-845 ）により得ること
ができる他、本発明者等が鹿児島県鹿屋市寿町にて採取
した土壌から分離したストレプトベルティシリウム属に
属する微生物ＳＫＨ−３５１３株を培養することによっ
ても得ることができる。In the present invention, lanthipeptin (Lanthi
opeptin) is the method of T. Miyaki et al. (The Journal of Ant
ibiotics: Vol.XLII, No.6, P837-845), and a microorganism SKH- belonging to the genus Streptoverticillium isolated from soil collected by the present inventors in Kotobuki-cho, Kagoshima Prefecture. It can also be obtained by culturing the 3513 strain.
【０００９】他方、デュラマイシン（Duramycin ）は、
市販工業薬品（SIGMA CHEMICAL CO.：Alphabetical Lis
t of Compounds, Product No.D3168）を使用することが
できる。これらのランチオペプチン（Lanthiopeptin ）
又はデュラマイシン（Duramycin ）を主成分とする抗レ
トロウイルス剤をＡＩＤＳ治療又は予防に用いる場合に
は、注射薬、経口薬、経皮吸収剤、経鼻吸収剤等一般的
に知られているいずれかの投与方法で使用することがで
きる。On the other hand, duramycin is
Commercial chemicals (SIGMA CHEMICAL CO .: Alphabetical Lis
t of Compounds, Product No. D3168) can be used. These lanthiopeptins
Or, when an antiretroviral agent containing duramycin as a main component is used for AIDS treatment or prophylaxis, it is generally known as an injection drug, an oral drug, a transdermal drug, a nasal drug, etc. Can be used in any administration method.
【００１０】以下に、本発明の効果を実施例により説明
する。The effects of the present invention will be described below with reference to examples.
【００１１】[0011]
【実施例】以下、実施例に従って本発明を更に詳細に説
明するが、本発明はこれによって限定されるものではな
い。The present invention will be described in more detail with reference to the following examples, but the present invention is not limited thereto.
【００１２】実施例１ランチオペプチン、デュラマイシンの抗ＨＩＶ活性 ランチオペプチン（Lanthiopeptin ）及びデュラマイシ
ン（Duramycin ）の抗ＨＩＶ−１活性をＭＴ−４細胞を
用いた以下の実験により測定した。Example 1 Anti-HIV Activities of Lantiopeptin and Duramycin The anti-HIV-1 activities of Lanthiopeptin and Duramycin were measured by the following experiment using MT-4 cells.
【００１３】本法はＨＩＶ感染によって引き起こされる
ＣＤ４陽性細胞の感染死と薬剤による抑制効果を判定す
るものであり、抗ＨＩＶ活性と細胞毒性を同時に且つ、
簡便に測定することが可能であることから優れた方法で
ある。This method is for determining the death of infection of CD4 positive cells caused by HIV infection and the inhibitory effect of the drug.
It is an excellent method because it can be easily measured.
【００１４】具体的実験方法は、以下の通りである。The concrete experimental method is as follows.
【００１５】１×１０4 個のＨＩＶ−１(HTLV-3B）に感
染させたＭＴ−４細胞と非感染のＭＴ−４細胞を種々の
濃度のランチオペプチン、ＡＺＴ等と共に96穴マイクロ
プレートの各穴に加え、37℃のＣＯ2 インキュベーター
中で５日間培養した後、3-(4,5-dim-ethyl-2-thiazoly
l)-2,5-diphenyl-2H tetrazolium bromide （以下『Ｍ
ＴＴ』と略記）を加え、更に２時間培養を続けた。この
間に生細胞に取り込まれたＭＴＴは、細胞中のミトコン
ドリアの有する酵素により還元、青紫色の水不溶性色素
（formazan）を生成した。次いで、５％Triton X-100を
含む塩酸酸性２−プロピルアルコール溶液を添加し、生
成した色素を可溶化させた後、 595nmにおける特異的吸
光度と 655nmにおける非特異的吸光度をマイクロプレー
トリーダー（BIO-RAD モデル3550）を用いて測定するこ
とにより、両者の差を求め、得られた数値から50％細胞
死阻止濃度（ＥＣ50値）、50％細胞毒性濃度（ＣＣ50
値）及び治療係数ＳＩ値（SI値＝CC50値／EC50値）を算
出した。その抗ＨＩＶアッセイ結果をＡＺＴ、ＤＤＩ、
ＤＤＣと共に表１に示す。なお、ＳＩ値は、細胞障害を
起こさず、ＨＩＶ感染による細胞障害を防御する濃度領
域でしかも正常細胞への毒性のない領域の表示として意
義がある。従って、薬効の点ではＥＣ50値は小さな程望
ましく、正常細胞への毒性の点ではＣＣ50値は大きな程
良い。さらに、ＳＩ値は、できるだけ大きな値程安全性
が高いことを示す。1 × 10 4 HIV-1 (HTLV-3B) -infected MT-4 cells and non-infected MT-4 cells were mixed with various concentrations of lantiopeptin, AZT and the like in 96-well microplates. After adding to each well and culturing in a CO 2 incubator at 37 ℃ for 5 days, 3- (4,5-dim-ethyl-2-thiazoly
l) -2,5-diphenyl-2H tetrazolium bromide (hereinafter “M
(TT ") (abbreviated as" TT "), and the culture was continued for another 2 hours. During this period, the MTT taken into the living cells was reduced by an enzyme possessed by mitochondria in the cells to produce a blue-violet water-insoluble pigment (formazan). Then, acid 2-propyl alcohol solution containing 5% Triton X-100 was added to solubilize the produced dye, and the specific absorbance at 595 nm and the non-specific absorbance at 655 nm were measured using a microplate reader (BIO- RAD model 3550) was used to determine the difference between the two values, and 50% cell death inhibitory concentration (EC50 value) and 50% cytotoxicity concentration (CC50) were obtained from the obtained values.
Value) and therapeutic index SI value (SI value = CC50 value / EC50 value) were calculated. The anti-HIV assay results are shown in AZT, DDI,
It is shown in Table 1 together with DDC. The SI value is significant as an indication of a concentration range that does not cause cell damage and protects against cell damage due to HIV infection and that is not toxic to normal cells. Therefore, the smaller the EC50 value is, the more desirable it is in terms of drug efficacy, and the larger the CC50 value is, the better it is in the toxicity to normal cells. Furthermore, the SI value indicates that the higher the value, the higher the safety.
【００１６】[0016]
【表１】 [Table 1]
【００１７】[0017]
【発明の効果】以上記述したごとく、本発明のランチオ
ペプチン（Lanthiopeptin ）又はデュラマイシン（Dura
mycin ）は、50％有効濃度（ＥＣ50値）が、それぞれ 5
8ng/ml及び 60ng/mlという低濃度で抗ＨＩＶ活性を示す
ため、ヒト免疫不全ウイルスによる感染症の治療又は予
防に極めて有用である。Industrial Applicability As described above, the lanthiopeptin or duramycin (Duramycin) of the present invention is used.
mycin) has a 50% effective concentration (EC50 value) of 5
Since it exhibits anti-HIV activity at concentrations as low as 8 ng / ml and 60 ng / ml, it is extremely useful for treating or preventing infectious diseases caused by human immunodeficiency virus.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 町田 誠 山口県岩国市飯田町２丁目８番１号 日本 製紙株式会社岩国技術研究所内 (72)発明者 村上 邦睦 山口県岩国市飯田町２丁目８番１号 日本 製紙株式会社岩国技術研究所内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Makoto Machida 2-8-1, Iida-cho, Iwakuni-shi, Yamaguchi Prefecture Iwakuni Research Laboratories, Nippon Paper Industries Co., Ltd. (72) Kunimitsu Murakami 2-chome, Iida-cho, Iwakuni-shi, Yamaguchi Prefecture No. 8-1 Nippon Paper Industries Co., Ltd. Iwakuni Research Institute
Claims (1)
はデュラマイシン（Duramycin ）を有効成分として含有
することを特徴とする抗レトロウイルス剤。1. An antiretroviral agent comprising lanthiopeptin or duramycin as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6222801A JP2783315B2 (en) | 1994-09-19 | 1994-09-19 | Antiretroviral agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6222801A JP2783315B2 (en) | 1994-09-19 | 1994-09-19 | Antiretroviral agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0892124A true JPH0892124A (en) | 1996-04-09 |
| JP2783315B2 JP2783315B2 (en) | 1998-08-06 |
Family
ID=16788114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6222801A Expired - Lifetime JP2783315B2 (en) | 1994-09-19 | 1994-09-19 | Antiretroviral agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2783315B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010254723A (en) * | 2002-07-15 | 2010-11-11 | Board Of Regents The Univ Of Texas System | Selected antibody and duramycin peptide binding to anionic phospholipid and aminophospholipid, and their use in treating viral infection and cancer |
| US7976868B2 (en) | 2002-07-15 | 2011-07-12 | Board Of Regents, The University Of Texas System | Liposomes comprising duramycin and anti-viral agents |
| US8653034B2 (en) | 2002-07-15 | 2014-02-18 | Board Of Regents, The University Of Texas System | Compositions and methods comprising phosphatidylethanolamine-binding peptide derivatives |
-
1994
- 1994-09-19 JP JP6222801A patent/JP2783315B2/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010254723A (en) * | 2002-07-15 | 2010-11-11 | Board Of Regents The Univ Of Texas System | Selected antibody and duramycin peptide binding to anionic phospholipid and aminophospholipid, and their use in treating viral infection and cancer |
| EP2281578A3 (en) * | 2002-07-15 | 2011-04-13 | Board of Regents, The University of Texas System | Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer |
| EP2283868A3 (en) * | 2002-07-15 | 2011-04-13 | Board of Regents, The University of Texas System | Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer |
| US7976868B2 (en) | 2002-07-15 | 2011-07-12 | Board Of Regents, The University Of Texas System | Liposomes comprising duramycin and anti-viral agents |
| JP4827411B2 (en) * | 2002-07-15 | 2011-11-30 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | Selected antibodies and duramycin peptides that bind to anionic and aminophospholipids and their use in the treatment of viral infections |
| US8653034B2 (en) | 2002-07-15 | 2014-02-18 | Board Of Regents, The University Of Texas System | Compositions and methods comprising phosphatidylethanolamine-binding peptide derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2783315B2 (en) | 1998-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harakeh et al. | Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells. | |
| Sarin et al. | Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone | |
| EP0439513B1 (en) | Composition for inhibiting transmission of aids | |
| CA2173328A1 (en) | HIV Protease Inhibitors | |
| US6046228A (en) | Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof | |
| US5434163A (en) | Treatment of Cryptococcus neoformans infection | |
| US4873265A (en) | Anti-infective methods and compositions | |
| WO1998001440A9 (en) | Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof | |
| WO1998032442A1 (en) | Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as medicines for treating aids | |
| Quesnel et al. | Synergism between chlorhexidine and sulphadiazine | |
| WO1999049830A2 (en) | Antiviral effect of propolis by inhibiting viral nucleic acid polymerases | |
| JPH0892124A (en) | Anti-retrovirus agent | |
| KR20000069296A (en) | Extracts of Salvia Species Having Antiviral Activity | |
| DE60006519T2 (en) | GLUTATHION REDUCTASE FOR THE TREATMENT AND PROPHYLAXIS OF AIDS | |
| SA96160669B1 (en) | Combined treatment of HIV infection with a protease inhibitor and a reverse transcriptase inhibitor with AZT | |
| EP0819380A1 (en) | Bacteriocidal, antibacterial and bacteriostatic composition | |
| Polacheck et al. | The susceptibility of Cryptococcus neoformans to an antimycotic agent (G2) from alfalfa | |
| US5714516A (en) | Anti-viral agents | |
| RU2204385C2 (en) | 2,4-dichlorobenzyl alcohol and amylmethacresol against hiv-infection | |
| US4897404A (en) | Anti-infective methods and compositions | |
| KR0124028B1 (en) | Use of prolylendopeptidase inhibitors in the treatment of aids | |
| US4895859A (en) | Anti-infective methods and compositions | |
| US4895857A (en) | Anti-infective methods and compositions | |
| CA1307740C (en) | Pharmaceutical preparation and method for inhibiting replication of htlv-iii (aids) virus | |
| CA1306694C (en) | Pharmaceutical preparation and method for inhibiting replication of htlv-iii (aids) virus |